Merck’s $1.1B Acquisition of Sirna Could Close by End of Year | GenomeWeb
NEW YORK (GenomeWeb News) — Merck today said that its acquisition of RNAi shop Sirna Therapeutics may close as early as this month.
 
Merck announced its plans to acquire Sirna for $1.1 billion in cash on Oct. 30. At the time, the company said it expected the deal to close by the first quarter of 2007.
Today Merck said it expects the deal to close “in late December 2006 or early in the first quarter of 2007.”
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.